Search results
Showing 91 to 105 of 1045 results for criteria
Evidence-based recommendations on pembrolizumab (Keytruda) with pemetrexed and platinum chemotherapy for untreated, metastatic, non-squamous non-small-cell lung cancer (NSCLC) in adults whose tumours have no epidermal growth factor receptor (EGFR)- or anaplastic lymphoma kinase (ALK)-positive mutations.
Topotecan for the treatment of relapsed small-cell lung cancer (TA184)
Evidence-based recommendations on topotecan for treating relapsed small-cell cancer in adults.
View recommendations for TA184Show all sections
Evidence-based recommendations on atezolizumab (Tecentriq) for untreated extensive-stage small-cell lung cancer in adults.
Unintentional injuries on the road: interventions for under 15s (PH31)
This guideline covers road speed limits, 20 mph zones and engineering measures to reduce speed or make routes safer.
This guideline covers mid-life approaches to delay or prevent the onset of dementia, disability and frailty in later life. The guideline aims to increase the amount of time that people can be independent, healthy and active in later life.
Ripretinib for treating advanced gastrointestinal stromal tumour after 3 or more treatments (TA881)
Evidence-based recommendations on ripretinib (Qinlock) for treating gastrointestinal stromal tumour in adults after 3 or more treatments.
Evidence-based recommendations on lutetium (177Lu) oxodotreotide (Lutathera) for treating unresectable or metastatic neuroendocrine tumours in adults.
The NICE integrated topic prioritisation manual provides an overview of the process through which NICE will identify new topics and updates for prioritisation, and the decision-making framework that will be utilised by the NICE prioritisation board. This manual updates and replaces NICE health technology evaluation topic selection; the manual
Show all sections
- Overview
- 1 Our transformation
- 2 Types of topics the manual covers
- 3 Topics that are not usually considered by NICE
- 4 Summary of the NICE-wide topic prioritisation process
- 5 Identifying priorities for the health and care system
- 6 Identifying new topics and updates of existing guidance
- 7 Eligibility criteria for using the prioritisation framework and direct routing to guidance development
Evidence-based recommendations on axitinib (Inlyta) for previously treated advanced renal cell carcinoma in adults.
Cetuximab for the treatment of locally advanced squamous cell cancer of the head and neck (TA145)
Evidence-based recommendations on cetuximab (Erbitux) for treating locally advanced squamous cell cancer of the head and neck in adults.
Evidence-based recommendations on lapatinib (Tyverb) and trastuzumab (Herceptin) for treating metastatic hormone receptor-positive breast cancer that overexpresses HER2 in adults.
Necitumumab for untreated advanced or metastatic squamous non-small-cell lung cancer (TA411)
Evidence-based recommendations on necitumumab (Portrazza) for treating locally advanced or metastatic epidermal growth factor receptor (EGFR)-expressing squamous non-small-cell lung cancer in adults who have not had chemotherapy.
Evidence-based recommendations on bevacizumab (Avastin), sorafenib (Nexavar), sunitinib (Sutent) and temsirolimus (Torisel) for treating advanced or metastatic renal cell carcinoma in adults.
Evidence-based recommendations on semaglutide (Wegovy) for managing overweight and obesity in adults.
neuropathic pain, particularly to provide more information about selection criteria and long-term outcomes, with clear documentation of...